Filtered By:
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 341 results found since Jan 2013.

Health Affairs May Issue: Prescription Drugs, Global Health & More
This study is an extension of Bai and Anderson’s 2015 Health Affairs study about hospitals with the highest markup over Medicare allowable costs. States investing more in social services and public health had healthier residents Policy makers are now placing more emphasis on the role of social determinants in influencing individual and population health. To date, though, little has been known about the correlation between state spending for social services and public health and the health of individuals. Elizabeth Bradley of Yale University and coauthors broke new ground by finding that people living in states that spen...
Source: Health Affairs Blog - May 2, 2016 Category: Health Management Authors: Lucy Larner Tags: Elsewhere@ Health Affairs Featured Health Affairs journal Source Type: blogs

Throwback Thursday: April 28th, 1986 (30 Years Ago): Anti-Tobacco Groups Blast Cigarette Companies for Not Supporting Development of a Safer Cigarette
April 28, 1986 (AP, New York): Today, a coalition of anti-smoking organizations, heath agencies, and researchers are attacking the nation's cigarette companies for failing to support the development of much safer cigarettes. Health officials complained that for many years, cigarette companies have had the technology to produce a much safer cigarette, but have failed to show any support for even the idea of manufacturing a safer product.Also today, a class-action lawsuit was filed against Philip Morris, R.J. Reynolds, Lorillard, Brown & Williamson and Liggett, alleging that each of these companies could easily have prod...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - April 28, 2016 Category: Addiction Source Type: blogs

The Scientist on BioViva's Initial Test of Human Gene Therapies
The Scientist has published a measured piece on the first results from BioViva's initial test of human gene therapy, telomerase and follistatin overexpression, and the broader context in which this single person test took place. The results indicate that the telomerase gene therapy most likely worked in the sense of delivering telomerase to a significant number of cells, including the immune cells used to measure average telomere length. That is an important thing to validate up front, before thinking about any sort of other outcomes, or expanding to a trial of some sort. Historically, gene therapies have proven to be high...
Source: Fight Aging! - April 25, 2016 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs

To Fight Antimicrobial Resistance, Allow FDA To Approve New Drugs For Limited Populations
Over the past several months, microbiologists and public health experts around the world have been alarmed by the discovery of a gene conferring resistance to colistin, a so-called “last resort” antibiotic. The gene, MCR-1, was discovered in China last year, and thereafter quickly identified in E. coli samples from six continents. Because this type of gene is highly transferable, it will, in all likelihood, spread to other hard-to-treat bacteria. What global health leaders have been warning of for years has now become reality. Now, more than ever, there is an urgent need for action to spur the innovation of antibiotics...
Source: Health Affairs Blog - April 5, 2016 Category: Health Management Authors: Allan Coukell Tags: Drugs and Medical Technology Featured Global Health Population Health Public Health Quality 21st Century Cures Act Antibiotic Resistance Antibiotics Congress FDA limited-population antibacterial drug MCR-1 PATH Act Research Source Type: blogs

Value Pricing For Drugs: Whose Value, What Price?
It is hard to read a newspaper these days without coming across a story about the high and ever increasing cost of drugs. The Wall Street Journal named drug prices the top health story of 2015. Stories about drug prices fall into two general categories. The first are stories about generic and other manufacturers who are not focused on innovation (like Turing Pharmaceuticals and Valeant) but who acquire generic drugs and increase the price dramatically without adding value while also making it impossible for competitors to manufacture the drug by controlling the distribution. While this problem is real, it is not the focus ...
Source: Health Affairs Blog - March 28, 2016 Category: Health Management Authors: Robert Rubin Tags: Costs and Spending Drugs and Medical Technology Featured Medicare ACOs Big Pharma cost effectiveness analysis high-cost drugs PCSK9 inhibitors QUALY value-based payment Source Type: blogs

Scientific Misconduct at Prestigious Research Centers
On January 23, 2009, the Office of Research Integrity made public their findings of scientific misconduct concerning a doctor who fabricated data for several grants projects funded by the NIH (1). The doctor was a former graduate student in the Department of Pathology, Harvard Medical School, a former research fellow and Instructor of Pathology, at Brigham and Women's Hospital in Boston, a former postdoctoral fellow in the Department of Biology, at the California Institute of Technology, and a former Associate Professor in the Department of Biology and the Center for Cancer Research at the Massachusetts Institute of Techno...
Source: Specified Life - March 24, 2016 Category: Information Technology Tags: ethics fraud Karolinska Institute ORI scientific misconduct Source Type: blogs

Unpacking Drug Price Spikes: Generics
In December 2013, seven generic equivalents were introduced for the branded antidepressant Cymbalta, which had just gone off patent. At that time, Cymbalta carried a price tag of $538 for a 30-day supply. Within a month that price dropped 27 percent, and the addition of four more generic equivalents slashed the price in half by the end of 2014. This is a perfect example of how the generic drug market is supposed to work, and often has worked since the 1984 launch of the Drug Price Competition and Patent Term Restoration Act, aka the Hatch-Waxman Amendments. Generic drugs were originally introduced as a means to safely redu...
Source: Health Affairs Blog - March 21, 2016 Category: Health Management Authors: Michael Alkire Tags: Drugs and Medical Technology Featured Payment Policy Quality Cymbalta FDA generic drugs Hatch-Waxman Act priority review Source Type: blogs

There They Go Again - the New England Medical Journal Publishes another Rant, this Time about Power Morcellation
In 2015, we noted (here and here) that the New England Journal of Medicine seemed to have been reduced to publishing rants about "pharmascolds" who are paranoid about conflicts of interest. Now there they go again.... BackgroundThe sad story about the risks of power morcellation for the treatment of fibroids has received considerable media attention.  The state of play through July, 2014 was described in a series of articles in the Cancer Letter of July 4, 2014. (Look here.) Uterine fibroids are a common affliction of women.  Their preferred surgical management had changed from open surgery to minimally invasive ...
Source: Health Care Renewal - March 20, 2016 Category: Health Management Tags: cancer FDA logical fallacies New England Journal of Medicine Partners Healthcare Source Type: blogs

CDC warns doctors about the dangers of prescribing opioid painkillers - The Washington Post
With no end to the nation's opioid crisis in sight, the federal government on Tuesday issued final recommendations that urge doctors to use more caution and consider alternatives before they prescribe highly addictive narcotic painkillers.This first national guidance on the subject is nonbinding, and doctors cannot be punished for failing to comply. But the head of the Centers for Disease Control and Prevention, which issued the guidelines, said the effort was critical to bringing about "a culture shift for patients and doctors.""We are waking up as a society to the fact that these are dangerous drugs,"...
Source: Psychology of Pain - March 16, 2016 Category: Anesthesiology Source Type: blogs

A New Federal Agency to Oversee Patient Safety?
By TEJAL GANDHI, MD Patient safety should be a major priority for the United States, and that requires designating a centralized entity or coordinating body to oversee efforts to ensure it. Such centralized oversight is one of the key recommendations of “Free from Harm,” a report published in December by the National Patient Safety Foundation. The report highlights the need to create a safety culture, since preventable medical errors in hospitals are estimated to result in as many as 440,000 deaths annually. That would make it the third leading cause of death – after heart disease and cancer. A new report by the U.S...
Source: The Health Care Blog - March 10, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized National Patient Safety Foundation Source Type: blogs

The Global Healthspan Policy Institute Wants Your Support in Lobbying for TAME Metformin Trial Funding
The Global Healthspan Policy Institute (GHPI) is a recently launched group whose principals are focused on much the same goals as the researchers of the Longevity Dividend initiative, which is to say pulling a lot more public funding into aging research aimed at extending healthy human life spans. The chosen methodology is the traditional one of lobbying and political action, aimed at politicians and bureaucrats who influence budgets relevant to the National Institutes of Health, the National Insitute on Aging in particular, and other public sources of medical research funding. The first public initiative for the GHPI is ...
Source: Fight Aging! - February 24, 2016 Category: Research Authors: Reason Tags: Activism, Advocacy and Education Source Type: blogs

FDA CDER Update 2016
We recently reported that 2015 resulted in the highest level of newly approved U.S. drugs in nineteen years. This reflects an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases. As has been reported, while speaking at a recent meeting in Washington, D.C., the U.S. Food and Drug Administration's Director of the Center for Drug Evaluation and Research (CDER), Janet Woodcock, noted the agency has moved to address the backlog of abbreviated new drug applications (NDA). Woodcock added that CDER is working to prepare for the emerging biosimilars market. Additionally, John Jenkins, Director of ...
Source: Policy and Medicine - January 28, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs

Fighting the injustice of health disparities: Honoring the legacies of Dr. Martin Luther King Jr. & Dr. John M. Eisenberg
The past several years I have run this post and because it continues to have a very important and relevant  message I am sharing it again. We, as a nation, have made progress and I believe Dr. King would be proud. But our work is far from complete – particularly where health care is concerned. Another doctor, Dr. John M. Eisenberg, a physician of tremendous stature whose life was also tragically cut short (not by an assassin’s bullet but by brain cancer) was equally passionate about the dignity of life and justice for all Americans. Dr. Eisenberg, who among other things, served as the Director of the Agency for Health...
Source: Disruptive Women in Health Care - January 18, 2016 Category: Consumer Health News Authors: dw at disruptivewomen.net Tags: Advocacy Source Type: blogs

DM / DNB Cardiology Entrance Mock Test 3
Please wait while the activity loads. If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled. If loading fails, click here to try again Click on the 'Start' button to begin the mock test. After answering all questions, click on the 'Get Results' button to display your score and the explanations. Start Congratulations - you have completed DM / DNB Cardiology Entrance Mock Test 3. You scored %%SCORE%% out of %%TOTAL%%. Your performance has been rated as %%RATING%% Your answers are hi...
Source: Cardiophile MD - January 17, 2016 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: General Cardiology Source Type: blogs

Stealth Public Relations and Health Advocacy, Special Pleadings and the Opposition to Guidelines Discouraging Overuse of Narcotics
As I have written before as a physician who saw too many dire results of intravenous drug abuse, I was amazed how narcotics were pushed as the treatment of choice for chronic pain in the 1990s, with the result that the US was once again engulfed in an epidemic of narcotic abuse and its effects.  In mid-December, 2015, as reported in the Washington Post,The nation continues to suffer through a widespread epidemic to prescription opioids and their illegal cousin, heroin. The CDC estimated that 20 percent of patients who complain about acute or chronic pain that is not from cancer are prescribed opioids. Health-care prov...
Source: Health Care Renewal - January 4, 2016 Category: Health Management Tags: CDC Cephalon conflicts of interest deception Endo Health Solutions Johnson and Johnson narcotics public relations Purdue Pharma stealth health policy advocacy Source Type: blogs